Avemar - Assisting with Melanoma Skin Cancer Treatment
A Common Illness
Melanoma is the fourth most common cancer in Australia; the risk of being diagnosed by age 85 is 1 in 14 for men and 1 in 24 for women. This skin disease is both a common and recognisable form of cancer. Malignant tumours are responsible for 75% of all deaths related to this disease. The risk of developing this disease increases with exposure to harsh UV radiation, particularly with episodes of sunburn (especially during childhood).
The first sign of this illness is the change in the look, colour and feel of an existing mole, freckle or blemish. The development of a new mole may also be a melanoma forming. It is important to notice the ABC's of the mole structure: Asymmetry, Border, Colour, Diameter and Elevation.
Conventional medicine offers the following melanoma skin cancer treatments: the skin cancer may be removed during radiation therapy, chemotherapy and surgery.
During or after the Melanoma Cancer Treatments, Avemar is an excellent addition as a complementary product. It enhances the quality of life, speeds up the recovery of normal immune functions and improves the sense of wellbeing of the individual.
Avemar - Providing relief
Medical researchers highly recommend the inclusion of Avemar into conventional melanoma skin cancer treatments such as chemotherapy, radiotherapy and surgery. In conjunction with conventional medical treatment for cancer, Avemar has been shown to reduce the progression of the skin disease and enhance overall survival of people with B16 melanomas and higher.
Avemar has antioxidant properties which improves the body's ability to put up a fight to the illness. The reduction in free oxygen radicals induced by Avemar is correlated with significant improvement in the quality of life for the patient.
Avemar has been shown to enhance the function of the immune system while some inhibiting effect of tumour growth has been shown.
Avemar as a nutraceutical in the treatment of high risk patients shows significant differences in both progression and overall survival of patients. High risk means that the people studied had melanomas that either were not able to be completely removed at the time of diagnosis, or were considered very likely to re-occur, even with the best available conventional treatment. The use of Avemar demonstrated a clear benefit to those using it. Dacarbazine or DTIC melanoma treatments are those approved by regulatory bodies- Avemar is one such medicine.
Avemar appears to exert an intense antioxidant activity by reducing free radicals and significantly improves the quality of life in patients with advanced cancer. Avemar is additionally beneficial as no side effects for patients have been demonstrated yet the side effects of conventional treatments are reduced.
Avemar is unique in that it is the only nutriment in its category: specifically approved for use as a complementary cancer treatment. To find out how Avemar could help you contact us today.
View CNN World Report
CNN WORLD REPORT 2006